GlaxoSmithKline (GSK) Prescription drugs noticed its consolidated internet revenue rise greater than two-folds through the September quarter. The pharmaceutical main posted a consolidated internet revenue of ₹204.24 crore for the quarter ended September 30, 2021. The corporate had reported a internet revenue of ₹76.47 crore in the identical interval of the earlier fiscal, marking a progress of virtually 270 per cent.
Consolidated income from operations through the interval underneath evaluate rose to ₹1,009.87 crore, in comparison with ₹879.32 crore within the year-ago interval, GSK Prescription drugs mentioned in a regulatory submitting opn Friday.
The corporate follows a January-December monetary 12 months.
“Our established manufacturers grew of their respective therapeutic portfolios. Augmentin and Calpol regained their place amongst the highest 5 manufacturers within the Indian Prescription drugs Market (1PM). Our promoted portfolio additionally gained market share, whereas merchandise from our innovation and specialty pipeline continued to make inroads to serve extra sufferers,” mentioned GSK Pharma Managing Director Sridhar Venkatesh.
The corporate continues to seek out methods to leverage improvements in rising applied sciences and ship even better worth to shareholders, he added.
“We additionally improved our operational efficiencies, pushed by gross sales progress and value rationalisation. We additionally improved our money place backed by working capital enhancements. We anticipate this optimistic momentum to proceed by means of the second half of the 12 months driving us in the direction of the higher finish of a significant efficiency enchancment,” Venkatesh famous.
Supply: Live Mint